Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis

Autor: Henrique Sérgio Moraes Coelho, Mário Reis Álvares-da-Silva, Ana de Lourdes Candolo Martinelli, Carlos Eduardo Brandão-Mello, Giovanni Faria Silva, Raymundo Paraná, Sara A. Lari, Hugo Cheinquer, Rakesh Tripathi, Li Liu, Maria Lucia Gomes Ferraz, Jose Valdez Ramalho-Madruga, Estevão P. Nunes, Mario G. Pessoa, Evaldo S. Affonso-de-Araújo, Tami Pilot-Matias, Paulo Roberto Abrão Ferreira, Juvencio Furtado, Katia Alves, Maria Cassia Mendes-Correa, Nancy S. Shulman, Daniel E. Cohen
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Cyclopropanes
Liver Cirrhosis
Male
Time Factors
Sustained Virologic Response
Specialties of internal medicine
Hepacivirus
Direct-acting antivirals
Gastroenterology
chemistry.chemical_compound
0302 clinical medicine
2-Naphthylamine
Anilides
030212 general & internal medicine
Advanced fibrosis
Sulfonamides
Dasabuvir
Valine
General Medicine
Middle Aged
Viral Load
Genotype 1
Drug Combinations
Treatment Outcome
RC581-951
Chronic hepatits C
RNA
Viral
030211 gastroenterology & hepatology
Drug Therapy
Combination
Female
Brazil
medicine.drug
Adult
medicine.medical_specialty
Macrocyclic Compounds
Genotype
Proline
Lactams
Macrocyclic
Antiviral Agents
03 medical and health sciences
Internal medicine
Ombitasvir/paritaprevir/ritonavir
Drug Resistance
Viral
Ribavirin
medicine
Humans
Adverse effect
Uracil
Aged
Ritonavir
Hepatology
business.industry
Hepatitis C
Chronic
Ombitasvir
Regimen
chemistry
Paritaprevir
Carbamates
business
Zdroj: Annals of Hepatology, Vol 17, Iss 6, Pp 959-968 (2018)
ISSN: 1665-2681
Popis: Introduction and aim: Approximately 650,000 people in Brazil have chronic hepatitis C virus (HCV) infection. We evaluated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) plus dasabuvir (DSV) with/without ribavirin (RBV) in an open-label multicenter phase 3b trial in treatment-naive or interferon (IFN) treatment-experienced Brazilian patients with advanced hepatic fibrosis (METAVIR F3/4) and HCV genotype (GT) 1 infection. Materials and methods: All patients received coformulated OBV/PTV/r daily + DSV twice daily (3-DAA). GT1a-infected patients received 3-DAA plus RBV for 12 weeks, except for prior pegIFN/RBV nonresponders with cirrhosis who were treated for 24 weeks. GT1b-infected patients received 3-DAA alone (F3) or in combination with RBV (F4) for 12 weeks. The primary endpoint was sustained virologic response (HCV RNA
Databáze: OpenAIRE
Externí odkaz: